Galectin-3 can promote macrophage differentiation to an M2-like phenotype and inhibit CD8+ T cell-mediated anti-tumor effects; therefore, galectin-3 deficiency or pharmacological blockade can significantly inhibit lung cancer progression [20]. Here, CD8A is linked to lung carcinoma.